Leveraging cutting-edge
scientific research and technology
Leveraging cutting-edge
scientific research and technology
Who we are
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.
Our mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our approach
By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
London, UK – September 22, 2020 (original) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental
ATAI adds MDMA biotech to growing list of psychedelic makers
But ATAI, the German-born biotech that has quickly become the most prominent private promoter and driver of psychedelic therapy, still thinks they have something to offer. Yesterday, the portfolio announced their latest subsidiary: EmpathBio.
From ‘party drug’ to PTSD treatment: ATAI launches EmpathBio to develop MDMA-based therapy
Treatment for post-traumatic stress disorder (PTSD) varies from patient to patient and can combine different
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
London, UK – September 22, 2020 (original) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental
INSIGHT NETWORK: Diving deep with Matthew W. Johnson
In this episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr. Matthew
INSIGHT NETWORK: A conversation with Robin Carhart-Harris
In the inaugural episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr.
YPO Psychedelic Medicine for Mental Health Group – A Conversation with Christian Angermayer
Join Richard Simon, Chair at YPO (Young Presidents Organization) Psychedelic Medicines for Mental Health Group,
INSIGHT NETWORK: Diving deep with Matthew W. Johnson
In this episode of the Insight Network podcast, ATAI’s Allan Malievsky chats with Dr. Matthew
Vast experience
and great access to deal flow
Vast experience
and great access to deal flow
Work with us
to improve the lives of millions of people
Work with us
to improve the lives of millions of people
WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.
Join the ATAI #InsightNetwork
Join the ATAI #InsightNetwork
Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space